Successful harvest of psilocybin mushrooms yields novel psychedelic molecules

Sintalica Bioscience Corp. announced it has cultivated, harvested and processed its first batch of psilocybin mushrooms and has synthesized psychedelic molecules with enhanced anti-inflammatory properties and no hallucinogenic effects.

According to a company press release, Sintalica also filed a provisional patent application for the pending therapeutics, which were produced in conjunction with the University of Messina following authorization from the Italian Ministry of Health.

“These molecules are critical to continuing the Sintalica preclinical testing program,” Bruce Linton, Sintalica chairman and co-founder, stated in the release. “We are confident our proprietary molecules and unique formulations will lead to breakthrough treatments for neuroinflammatory diseases.”

The company’s research and drug development program concentrates on neurodegenerative disorders, such as chronic neuropathic pain from spinal cord injury and fibromyalgia.

“The successful cultivation of mushrooms combined with the synthesis of unique non-hallucinogenic molecules is a big achievement for Sintalica, the University of Messina and Italy’s drug development industry,” Salvatore Cuzzocrea, professor of pharmacology at the University of Messina, said in the release. “We are now looking forward to starting our drug development program’s next phase.”